Meeting
2017 ASCO Annual Meeting
A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC).
Authors
Sergei Tjulandin
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
Sergei Tjulandin , Mikhail Fedyanin , Vladimir Ivanovich Vladimirov , Vladimir Kostorov , Alla Sergeevua Lisyanskaya , Ludmila Krikunova , Andrew Cakana , Valeria Azarova , Oksana Karavaeva , Natalia Vostokova , Sergey Baranovsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02948075
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5541)
DOI
10.1200/JCO.2017.35.15_suppl.5541
Abstract #
5541
Poster Bd #
363
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Kathleen N. Moore
Poster
2022 ASCO Genitourinary Cancers Symposium
Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).
First Author: Guru P. Sonpavde
Poster
2016 ASCO Annual Meeting
Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02.
First Author: Albert Font
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu